MedTrace Logo

the Role of Ivabradine in Causing AF in Patients With Chronic Coronary Syndrome

NCT05168189 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2021-12-28

No results posted yet for this study

Summary

This study is aiming to detect the possibility of Ivabradine's role in the development of atrial fibrillation in chronic coronary syndrome patients with No structural heart disease.

Conditions

  • AF - Atrial Fibrillation

Interventions

DRUG

Ivabradine

follow up chronic coronary syndrome patients receiving Ivabradine for ( 6 months ) if the participants develop atrial fibrillation using 24 hours holter .

DIAGNOSTIC_TEST

transthoracic echo

performing baseline transthoracic echo for all patients to exclude any chamber dilatation

DEVICE

24 hours holter

perform 24 hours Holter monitoring for all patients at the start of the study and follow up after 6 months

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Salwa R. Demitry, PhD · Professor at cardiovascular medicine department , assiut university

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-31
Primary Completion
2023-12-31
Completion
2024-01-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05168189 on ClinicalTrials.gov